Anti-TNF therapy in Crohn's disease: A balance between a targeted therapeutic approach and drug-induced immunogenicity

Research output: Contribution to journalArticle

Abstract

Evaluation of: Schreiber S, Khaliq-Kareemi M, Laurence IC et al.; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357, 239–250 (2007). Crohn's disease is a chronic idiopathic inflammatory bowel disorder with no known cure. Patients generally require drug therapy over their lifetime in order to induce and maintain disease remission and an improved quality of life. Although anti-TNF therapies have proven efficacy in the treatment of patients with Crohn's disease, not all patients respond, while others show a loss of efficacy over time on maintenance therapy. The risk for immunogenicity with certain forms of anti-TNF therapy has led to the development of novel biologics, including certolizumab pegol. This paper evaluates the results of a large randomized placebo-controlled trial with certolizumab pegol in the maintenance (26 weeks) of remission in patients with moderate-to-severe Crohn's disease.

Original languageEnglish (US)
Pages (from-to)233-237
Number of pages5
JournalExpert Review of Gastroenterology and Hepatology
Volume1
Issue number2
DOIs
StatePublished - Dec 1 2007

Fingerprint

Crohn Disease
Pharmaceutical Preparations
Therapeutics
Biological Products
Randomized Controlled Trials
Placebos
Maintenance
Quality of Life
Research Personnel
Drug Therapy
Certolizumab Pegol

Keywords

  • Crohn's disease
  • immunogenicity
  • inflammatory bowel disease TNF-α

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

@article{81bb3e6ed6414920855373455f895a6f,
title = "Anti-TNF therapy in Crohn's disease: A balance between a targeted therapeutic approach and drug-induced immunogenicity",
abstract = "Evaluation of: Schreiber S, Khaliq-Kareemi M, Laurence IC et al.; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357, 239–250 (2007). Crohn's disease is a chronic idiopathic inflammatory bowel disorder with no known cure. Patients generally require drug therapy over their lifetime in order to induce and maintain disease remission and an improved quality of life. Although anti-TNF therapies have proven efficacy in the treatment of patients with Crohn's disease, not all patients respond, while others show a loss of efficacy over time on maintenance therapy. The risk for immunogenicity with certain forms of anti-TNF therapy has led to the development of novel biologics, including certolizumab pegol. This paper evaluates the results of a large randomized placebo-controlled trial with certolizumab pegol in the maintenance (26 weeks) of remission in patients with moderate-to-severe Crohn's disease.",
keywords = "Crohn's disease, immunogenicity, inflammatory bowel disease TNF-α",
author = "Carmelo Cuffari",
year = "2007",
month = "12",
day = "1",
doi = "10.1586/17474124.1.2.233",
language = "English (US)",
volume = "1",
pages = "233--237",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Anti-TNF therapy in Crohn's disease

T2 - A balance between a targeted therapeutic approach and drug-induced immunogenicity

AU - Cuffari, Carmelo

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Evaluation of: Schreiber S, Khaliq-Kareemi M, Laurence IC et al.; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357, 239–250 (2007). Crohn's disease is a chronic idiopathic inflammatory bowel disorder with no known cure. Patients generally require drug therapy over their lifetime in order to induce and maintain disease remission and an improved quality of life. Although anti-TNF therapies have proven efficacy in the treatment of patients with Crohn's disease, not all patients respond, while others show a loss of efficacy over time on maintenance therapy. The risk for immunogenicity with certain forms of anti-TNF therapy has led to the development of novel biologics, including certolizumab pegol. This paper evaluates the results of a large randomized placebo-controlled trial with certolizumab pegol in the maintenance (26 weeks) of remission in patients with moderate-to-severe Crohn's disease.

AB - Evaluation of: Schreiber S, Khaliq-Kareemi M, Laurence IC et al.; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357, 239–250 (2007). Crohn's disease is a chronic idiopathic inflammatory bowel disorder with no known cure. Patients generally require drug therapy over their lifetime in order to induce and maintain disease remission and an improved quality of life. Although anti-TNF therapies have proven efficacy in the treatment of patients with Crohn's disease, not all patients respond, while others show a loss of efficacy over time on maintenance therapy. The risk for immunogenicity with certain forms of anti-TNF therapy has led to the development of novel biologics, including certolizumab pegol. This paper evaluates the results of a large randomized placebo-controlled trial with certolizumab pegol in the maintenance (26 weeks) of remission in patients with moderate-to-severe Crohn's disease.

KW - Crohn's disease

KW - immunogenicity

KW - inflammatory bowel disease TNF-α

UR - http://www.scopus.com/inward/record.url?scp=85027916347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027916347&partnerID=8YFLogxK

U2 - 10.1586/17474124.1.2.233

DO - 10.1586/17474124.1.2.233

M3 - Article

AN - SCOPUS:85027916347

VL - 1

SP - 233

EP - 237

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 2

ER -